Skip to main content
Premium Trial:

Request an Annual Quote

Proxeon Raises $2.4M from VC Investors

NEW YORK (GenomeWeb News) – Danish proteomics firm Proxeon has raised DKK14 million ($2.4 million) in a round of private financing from venture capital investors.

The firm did not say in its statement who the venture capital investors are for this round, but according to the firm's website investment firms Vecata and Inventure Capital are among its investors.

Proxeon said that the investment is expected to be sufficient to help the firm reach positive cash flow. It also noted that it expects to record full-year 2008 revenue growth of more than 60 percent.

Proxeon CEO Martin Winge noted that the firm has shipped more than 100 of its Easy-nLC systems for nanoscale chromatography since its launch in 2006.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.